Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-075-4 | CAS number: 78-00-2
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
Several studies are used as a weight of evidence approach to indicate that TEL distributes quickly through the body rapidly converting enzymically by the liver to TriEL and inorganic lead and causes damage to all major organs, in particular the liver, kidney and brain.
TEL is highly volatile and readily dissolvable in lipids. It is therefore easily inhaled and rapidly absorbed through the skin. Its elimination through faeces and urine is slow. It is metabolised in the liver to triethyllead (TriEL). TEL reaches its highest concentration in the liver followed by the kidney and brain affecting both central nervous and peripheral transmitters, myelin synthesis and metabolism.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
TEL is highly volatile and is therefore easily inhaled. It is readily dissolvable in lipids. and rapidly absorbed through the skin (Kehoe 1976). Its elimination through faeces and urine is slow. It is metabolised in the liver to triethyllead (TriEL). TEL reaches its highest concentration in the liver followed by the kidney and brain affecting both central nervous and peripheral transmitters, myelin synthesis and metabolism. (Arai et al 1983)
After absorption, TEL is distributed rapidly in the blood through the body. The half life in the blood is 13 seconds. The maximum concentration is reached in the blood and liver after 1 -3 hours. In the kidney about 11% of the exposure dose accumulates within 20 hours. After i.p administration, maximium tissue levels in the whole animal of TEL in the form of TriEL were measured after 5 days in rats (Hayakawa 1972a).
After intravenous administration of TEL , inorganic lead is almost the only excreted product present in the faeces. More than 2/3 of the dose is eliminated this way with the balance in urine. After 24 hours, 12% of the total lead is present in faeces; 90% in the form of inorganic lead (Arai et al 1983).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
